	US 12,247,068 B2
	Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders
Gökhan S. Hotamisligil, Wellesley, MA (US); Mehmet F. Burak, Brighton, MA (US); Feyza Engin, Madison, WI (US); Scott B. Widenmaier, Brighton, MA (US); Karen Inouye, Boston, MA (US); Elisabeth Helen Roberts, Slough (GB); Adrian Richard Moore, Slough (GB); Carl Brendan Doyle, Slough (GB); Ralph Adams, Slough (GB); Karine Jeannine Madeleine Hervé, Vancouver (CA); Shauna Mhairi Wales, Slough (GB); and Kerry Louise Tyson, Slough (GB)
Assigned to President and Fellows of Harvard College
Filed by President and Fellows of Harvard College, Cambridge, MA (US)
Filed on May 21, 2021, as Appl. No. 17/327,170.
Application 17/327,170 is a continuation of application No. 16/197,066, filed on Nov. 20, 2018, granted, now 11,014,979.
Application 16/197,066 is a continuation of application No. 15/143,162, filed on Apr. 29, 2016, granted, now 10,160,798, issued on Dec. 25, 2018.
Claims priority of provisional application 62/268,257, filed on Dec. 16, 2015.
Claims priority of provisional application 62/232,148, filed on Sep. 24, 2015.
Claims priority of provisional application 62/155,217, filed on Apr. 30, 2015.
Prior Publication US 2022/0089705 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 39/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/6018 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

19 Claims

1. A method of reducing or attenuating the biological activity of secreted adipocyte protein 2 (aP2) in a human comprising administering an effective amount of a humanized anti-aP2 monoclonal antibody or antigen binding agent comprising:

(a) a light chain variable region comprising:

(i) a CDR-L1 complementarity determining region (CDR) comprising the amino acid sequence of Seq. ID No. 7;

(ii) a CDR-L2 CDR comprising the amino acid sequence of Seq. ID No. 8; and

(iii) a CDR-L3 CDR comprising an amino acid sequence selected from the group consisting of Seq. ID No. 9, Seq. ID No. 10, Seq. ID No. 11, and Seq. ID No. 12; and

(b) a heavy chain variable region comprising:

(i) a CDR-H1 CDR comprising the amino acid sequence of Seq. ID No. 14;

(ii) a CDR-H2 CDR comprising an amino acid sequence selected from the group consisting of Seq. ID No. 16 and Seq. ID No. 17; and

(iii) a CDR-H3 CDR comprising an amino acid sequence selected from the group consisting of Seq. ID No. 19 and Seq. ID No. 20.